DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. - Stockmann AP; Vincent S; Herschelman L; Huang CS; Ma J; Fallon D; Kirby P; Gutierrez E; Talbot D; Hicks SW; Wagtmann N; Cheung AF (Cell reports. Medicine, 2026)